This page has only limited features, please log in for full access.
Background Diastolic dysfunction is highly prevalent in patients with type 2 diabetes mellitus (T2DM) and is associated with overweight, glucose dysregulation and coronary artery disease (CAD). The GLP-1 receptor agonist, liraglutide, has shown to induce weight loss and improve metabolic factors, thus modulating factors associated with diastolic dysfunction. We have previously reported the effects of liraglutide on systolic function, and in this current study we explore the effects of liraglutide on diastolic function parameters in patients with stable CAD, preserved left ventricular ejection fraction (LVEF), and newly diagnosed T2DM. Methods Thirty subjects were randomized to liraglutide or placebo intervention for 12 + 12-weeks in this double-blind cross-over study. 2D-echocardiography using tissue velocity imaging was used for assessment of diastolic function parameters. Early diastolic filling velocity (E), late atrial filling velocity (A), E-wave deceleration time (EDT) and E/A ratio was assessed from the pulse wave (PW)-Doppler velocity recording of the mitral inflow. Peak early diastolic annular velocities (e′) was measured from color tissue doppler images. Results Liraglutide, when compared to placebo, induced a significant reduction in average e′ and lateral e′ velocities (– 0.57 cm/s [– 1.05 to − 0.08] and –0.74 cm/s [–1.32 to –0.15], respectively). Adjusted for the concomitant increase in HR (+ 6.16 bpm [0.79 to 11.54], the changes were not significant. No significant changes in other diastolic function parameters were observed. Conclusions Liraglutide therapy did not improve any diastolic function parameters in subjects with T2DM, CAD, and preserved LVEF. Instead, a deterioration in e’ was observed, which was associated to an increase in heart rate induced by liraglutide therapy. Trial registration Clinical Trial Registration: http://www.clinicaltrials.gov (unique identifier: NCT01595789) (first submitted May 8, 2012)
Preman Kumarathurai; Ahmad Sajadieh; Christian Anholm; Ole P. Kristiansen; Steen B. Haugaard; Olav W. Nielsen. Effects of liraglutide on diastolic function parameters in patients with type 2 diabetes and coronary artery disease: a randomized crossover study. Cardiovascular Diabetology 2021, 20, 1 -7.
AMA StylePreman Kumarathurai, Ahmad Sajadieh, Christian Anholm, Ole P. Kristiansen, Steen B. Haugaard, Olav W. Nielsen. Effects of liraglutide on diastolic function parameters in patients with type 2 diabetes and coronary artery disease: a randomized crossover study. Cardiovascular Diabetology. 2021; 20 (1):1-7.
Chicago/Turabian StylePreman Kumarathurai; Ahmad Sajadieh; Christian Anholm; Ole P. Kristiansen; Steen B. Haugaard; Olav W. Nielsen. 2021. "Effects of liraglutide on diastolic function parameters in patients with type 2 diabetes and coronary artery disease: a randomized crossover study." Cardiovascular Diabetology 20, no. 1: 1-7.
Background Hyperinsulinemia aggravates insulin resistance and cardio-vascular disease. How the insulinotropic glucagon-like peptide-1 receptor agonist liraglutide in a physiologic post-prandial setting may act on pancreatic alpha and beta-cell function in patients with coronary artery disease (CAD) and type 2 diabetes (T2DM) is less clear. Methods Insulin resistant patients with established CAD and newly diagnosed well-controlled T2DM were recruited to a placebo-controlled, cross-over trial with two treatment periods of 12 weeks and a 2 weeks wash-out period before and in-between. Treatment was liraglutide or placebo titrated from 0.6 mg q.d. to 1.8 mg q.d. within 4 weeks and metformin titrated from 500 mg b.i.d to 1000 mg b.i.d. within 4 weeks. Before and after intervention in both 12 weeks periods insulin, C-peptide, glucose, and glucagon were measured during a meal test. Beta-cell function derived from the oral glucose tolerance setting was calculated as changes in insulin secretion per unit changes in glucose concentration (Btotal) and whole-body insulin resistance using ISIcomposite. Results Liraglutide increased the disposition index [Btotal × ISIcomposite, by 40% (n = 24, p < 0.001)] compared to placebo. Post-prandial insulin and glucose was reduced by metformin in combination with liraglutide and differed, but not significantly different from placebo, moreover, glucagon concentration was unaffected. Additionally, insulin clearance tended to increase during liraglutide therapy (n = 26, p = 0.06). Conclusions The insulinotropic drug liraglutide may without increasing the insulin concentration reduce postprandial glucose but not glucagon excursions and improve beta-cell function in newly diagnosed and well-controlled T2DM. Trial registration Clinicaltrials.gov ID: NCT01595789
Christian Anholm; Preman Kumarathurai; Anders Jürs; Lene Rørholm Pedersen; Olav Wendelboe Nielsen; Ole Peter Kristiansen; Mogens Fenger; Jens Juul Holst; Sten Madsbad; Ahmad Sajadieh; Steen Bendix Haugaard. Liraglutide improves the beta-cell function without increasing insulin secretion during a mixed meal in patients, who exhibit well-controlled type 2 diabetes and coronary artery disease. Diabetology & Metabolic Syndrome 2019, 11, 42 .
AMA StyleChristian Anholm, Preman Kumarathurai, Anders Jürs, Lene Rørholm Pedersen, Olav Wendelboe Nielsen, Ole Peter Kristiansen, Mogens Fenger, Jens Juul Holst, Sten Madsbad, Ahmad Sajadieh, Steen Bendix Haugaard. Liraglutide improves the beta-cell function without increasing insulin secretion during a mixed meal in patients, who exhibit well-controlled type 2 diabetes and coronary artery disease. Diabetology & Metabolic Syndrome. 2019; 11 (1):42.
Chicago/Turabian StyleChristian Anholm; Preman Kumarathurai; Anders Jürs; Lene Rørholm Pedersen; Olav Wendelboe Nielsen; Ole Peter Kristiansen; Mogens Fenger; Jens Juul Holst; Sten Madsbad; Ahmad Sajadieh; Steen Bendix Haugaard. 2019. "Liraglutide improves the beta-cell function without increasing insulin secretion during a mixed meal in patients, who exhibit well-controlled type 2 diabetes and coronary artery disease." Diabetology & Metabolic Syndrome 11, no. 1: 42.
Heart failure with preserved ejection fraction (HFpEF) involves half of hospitalised patients with heart failure (HF), but estimates vary due to unclear diagnostic criteria. We performed a prospective observational study of hospitalised patients admitted with dyspnoea. The aim was to apply contemporary guidelines to diagnose HF due to valvular disease (HFvhd), HF due to reduced ejection fraction (HFrEF), HF due to midrange EF (HFmrEF) and HFpEF in relation to presumed cardiac or non-cardiac dyspnoea.MethodsWe included consecutive hospitalised patients with presumed HF or dyspnoea and excluded patients with acute coronary syndrome, estimated glomerular filtration rate ResultsOf 707 eligible patients, we included 370 patients of whom 75 had non-cardiac dyspnoea. Of these, 10% (38/370) had no cardiac dysfunction. Cardiac dysfunction consisted of 18.4%, HFvhd, 30.1% HFrEF, 10.2% HFmrEF and 41.3% HFpEF. HFpEF was twice as common in presumptive non-cardiac dyspnoea versus cardiac dyspnoea (71% vs 34%, pConclusionHF according to contemporary criteria applied to 90% of patients admitted with dyspnoea and elevated NT-proBNP irrespective of the presumptive cause of dyspnoea, of whom 10% had HFmrEF and 41% HFpEF. However, significant non-cardiac diagnoses related to 9 out of 10 with HFpEF with pulmonary disease as the predominant adjudicated problem.
Olav Wendelboe Nielsen; Nana Valeur; Ahmad Sajadieh; Andreas Fabricius-Bjerre; Christian Malchau Carlsen; Lars Kober. Echocardiographic subtypes of heart failure in consecutive hospitalised patients with dyspnoea. Open Heart 2019, 6, e000928 .
AMA StyleOlav Wendelboe Nielsen, Nana Valeur, Ahmad Sajadieh, Andreas Fabricius-Bjerre, Christian Malchau Carlsen, Lars Kober. Echocardiographic subtypes of heart failure in consecutive hospitalised patients with dyspnoea. Open Heart. 2019; 6 (1):e000928.
Chicago/Turabian StyleOlav Wendelboe Nielsen; Nana Valeur; Ahmad Sajadieh; Andreas Fabricius-Bjerre; Christian Malchau Carlsen; Lars Kober. 2019. "Echocardiographic subtypes of heart failure in consecutive hospitalised patients with dyspnoea." Open Heart 6, no. 1: e000928.
Aim Serelaxin is a recombinant human relaxin‐2 hormone, which confers receptor‐mediated vasodilatation in a tissue‐specific fashion. The RELAX‐AHF‐EU study assessed the effect of serelaxin when added to standard‐of‐care (SoC) therapy on worsening heart failure (WHF)/all‐cause death through Day 5 in patients hospitalised for acute heart failure (AHF) in Europe. Methods and results This multicentre, prospective, randomised, open‐label, blinded‐endpoint validation study enrolled hospitalised AHF patients and randomised (2:1) eligible patients (mild‐to‐moderate renal impairment and systolic blood pressure ≥ 125 mmHg) within 16 h of presentation with signs/symptoms of AHF, to receive 48 h intravenous infusion of 30 μg/kg/day serelaxin + SoC or SoC alone. The primary endpoint was adjudicated WHF/all‐cause death through Day 5. Of 3183 patients targeted, 2666 were randomised when the study was terminated early by the sponsor due to the neutral results of the pivotal RELAX‐AHF‐2 study. Adjudicated WHF/all‐cause death through Day 5 was significantly reduced in the serelaxin + SoC vs. SoC group (5.0% vs. 6.9%; hazard ratio 0.71; 95% confidence interval 0.51–0.98; P = 0.0172) (absolute risk reduction 1.9%, number needed to treat 53). The difference between treatment groups was not significant for WHF/all‐cause death/heart failure rehospitalisation through Day 14 and length of hospital stay. A significantly smaller proportion of patients in the serelaxin + SoC vs. SoC group experienced persistent heart failure signs/symptoms at each visit until Day 4, or renal deterioration through Day 5 (all P ≤ 0.01). Overall incidence of treatment‐emergent adverse events was comparable between treatment groups. Hypotension and decrease in haemoglobin/haematocrit were more frequent in the serelaxin + SoC group. Conclusion When added to SoC, serelaxin reduced adjudicated WHF or all‐cause death through Day 5 in AHF patients. The results from this open‐label study should be considered in the context of the totality of the double‐blind, randomised evidence on serelaxin in AHF.
Aldo P. Maggioni; José López-Sendón; Olav W. Nielsen; Jonas Hallén; Maryam Aalamian-Mattheis; Yaqin Wang; Georg Ertl. Efficacy and safety of serelaxin when added to standard of care in patients with acute heart failure: results from a PROBE study, RELAX‐AHF‐EU. European Journal of Heart Failure 2019, 21, 322 -333.
AMA StyleAldo P. Maggioni, José López-Sendón, Olav W. Nielsen, Jonas Hallén, Maryam Aalamian-Mattheis, Yaqin Wang, Georg Ertl. Efficacy and safety of serelaxin when added to standard of care in patients with acute heart failure: results from a PROBE study, RELAX‐AHF‐EU. European Journal of Heart Failure. 2019; 21 (3):322-333.
Chicago/Turabian StyleAldo P. Maggioni; José López-Sendón; Olav W. Nielsen; Jonas Hallén; Maryam Aalamian-Mattheis; Yaqin Wang; Georg Ertl. 2019. "Efficacy and safety of serelaxin when added to standard of care in patients with acute heart failure: results from a PROBE study, RELAX‐AHF‐EU." European Journal of Heart Failure 21, no. 3: 322-333.
URL: https://www.clinicaltrials.gov . Unique identifier: NCT02061891.
Klaus Kofoed; Henning Kelbæk; Peter Riis Hansen; Christian Torp-Pedersen; Dan Høfsten; Lene Kløvgaard; Lene Holmvang; Steffen Helqvist; Erik Jørgensen; Søren Galatius; Frants Pedersen; Lia Bang; Kari Saunamaki; Peter Clemmensen; Jesper J. Linde; Merete Heitmann; Olav Wendelboe Nielsen; Ilan E. Raymond; Ole Peter Kristiansen; Ida Hastrup Svendsen; Jan Bech; Maria Helena Dominguez Vall-Lamora; Charlotte Kragelund; Thomas Fritz Hansen; Jens Hove; Tem Jørgensen; Gitte G. Fornitz; Rolf Steffensen; Birgit Jurlander; Jawdat Abdulla; Stig Lyngbæk; Hanne Elming; Susette Krohn Therkelsen; Ulrik Abildgaard; Jan Skov Jensen; Gunnar Gislason; Lars V. Køber; Thomas Engstrøm. Early Versus Standard Care Invasive Examination and Treatment of Patients With Non-ST-Segment Elevation Acute Coronary Syndrome. Circulation 2018, 138, 2741 -2750.
AMA StyleKlaus Kofoed, Henning Kelbæk, Peter Riis Hansen, Christian Torp-Pedersen, Dan Høfsten, Lene Kløvgaard, Lene Holmvang, Steffen Helqvist, Erik Jørgensen, Søren Galatius, Frants Pedersen, Lia Bang, Kari Saunamaki, Peter Clemmensen, Jesper J. Linde, Merete Heitmann, Olav Wendelboe Nielsen, Ilan E. Raymond, Ole Peter Kristiansen, Ida Hastrup Svendsen, Jan Bech, Maria Helena Dominguez Vall-Lamora, Charlotte Kragelund, Thomas Fritz Hansen, Jens Hove, Tem Jørgensen, Gitte G. Fornitz, Rolf Steffensen, Birgit Jurlander, Jawdat Abdulla, Stig Lyngbæk, Hanne Elming, Susette Krohn Therkelsen, Ulrik Abildgaard, Jan Skov Jensen, Gunnar Gislason, Lars V. Køber, Thomas Engstrøm. Early Versus Standard Care Invasive Examination and Treatment of Patients With Non-ST-Segment Elevation Acute Coronary Syndrome. Circulation. 2018; 138 (24):2741-2750.
Chicago/Turabian StyleKlaus Kofoed; Henning Kelbæk; Peter Riis Hansen; Christian Torp-Pedersen; Dan Høfsten; Lene Kløvgaard; Lene Holmvang; Steffen Helqvist; Erik Jørgensen; Søren Galatius; Frants Pedersen; Lia Bang; Kari Saunamaki; Peter Clemmensen; Jesper J. Linde; Merete Heitmann; Olav Wendelboe Nielsen; Ilan E. Raymond; Ole Peter Kristiansen; Ida Hastrup Svendsen; Jan Bech; Maria Helena Dominguez Vall-Lamora; Charlotte Kragelund; Thomas Fritz Hansen; Jens Hove; Tem Jørgensen; Gitte G. Fornitz; Rolf Steffensen; Birgit Jurlander; Jawdat Abdulla; Stig Lyngbæk; Hanne Elming; Susette Krohn Therkelsen; Ulrik Abildgaard; Jan Skov Jensen; Gunnar Gislason; Lars V. Køber; Thomas Engstrøm. 2018. "Early Versus Standard Care Invasive Examination and Treatment of Patients With Non-ST-Segment Elevation Acute Coronary Syndrome." Circulation 138, no. 24: 2741-2750.
The chymase inhibitor fulacimstat is developed as a first‐in‐class treatment option for the inhibition of adverse cardiac remodeling in patients with left ventricular dysfunction (LVD) after acute myocardial infarction (MI). The aim of the study was to examine the safety and tolerability of fulacimstat in patients with LVD after remote MI. A multicenter, multinational randomized, placebo‐controlled study was performed in clinically stable patients (40–79 years of age, left ventricular ejection fraction ≤ 45% because of MI in medical history) who were on stable evidence‐based standard‐of‐care therapies for LVD post‐MI including an angiotensin converting enzyme inhibitor or angiotensin receptor blocker at doses of at least half the recommended target dose. Patients were treated for 2 weeks with either placebo (n = 12) or 4 different doses of fulacimstat (5 mg twice daily, n = 9; 10 mg twice daily, n = 9; 25 mg twice daily, n = 10; 50 mg once daily, n = 9). Fulacimstat was safe and well tolerated at all examined doses. There were no clinically relevant effects on vital signs or potassium levels compared with placebo treatment. Mean plasma concentrations of fulacimstat increased with the administered dose and reached exposures predicted to be therapeutically active. The safety profile and the absence of effects on blood pressure or heart rate in a chronic patient population having similar comorbidities and receiving similar comedication as patients after acute MI support future clinical trials with fulacimstat in patients after acute MI.
Hans-Dirk Düngen; Lars Kober; Savina Nodari; Morten Schou; Christiane Otto; Michael Becka; Friederike Kanefendt; Bernhard R. Winkelmann; Gunnar Gislason; Frank Richard; Olav Wendelboe Nielsen; Mihai Gheorghiade; Michele Senni. Safety and Tolerability of the Chymase Inhibitor Fulacimstat in Patients With Left Ventricular Dysfunction After Myocardial Infarction—Results of the CHIARA MIA 1 Trial. Clinical Pharmacology in Drug Development 2018, 8, 942 -951.
AMA StyleHans-Dirk Düngen, Lars Kober, Savina Nodari, Morten Schou, Christiane Otto, Michael Becka, Friederike Kanefendt, Bernhard R. Winkelmann, Gunnar Gislason, Frank Richard, Olav Wendelboe Nielsen, Mihai Gheorghiade, Michele Senni. Safety and Tolerability of the Chymase Inhibitor Fulacimstat in Patients With Left Ventricular Dysfunction After Myocardial Infarction—Results of the CHIARA MIA 1 Trial. Clinical Pharmacology in Drug Development. 2018; 8 (7):942-951.
Chicago/Turabian StyleHans-Dirk Düngen; Lars Kober; Savina Nodari; Morten Schou; Christiane Otto; Michael Becka; Friederike Kanefendt; Bernhard R. Winkelmann; Gunnar Gislason; Frank Richard; Olav Wendelboe Nielsen; Mihai Gheorghiade; Michele Senni. 2018. "Safety and Tolerability of the Chymase Inhibitor Fulacimstat in Patients With Left Ventricular Dysfunction After Myocardial Infarction—Results of the CHIARA MIA 1 Trial." Clinical Pharmacology in Drug Development 8, no. 7: 942-951.
Background Whether there is an association between sleep apnea (SA) and the risk of developing heart failure (HF) is unclear. Furthermore, it has never been established whether continuous positive airway pressure (CPAP) therapy can prevent development of HF. We aimed to investigate SA patients’ risk of developing HF and the association of CPAP therapy. Methods and Results Using nationwide databases, the entire Danish population was followed from 2000 until 2012. patients with SA receiving and not receiving CPAP therapy were identified and compared with the background population. The primary end point was first‐time hospital contact for HF and adjusted incidence rate ratios of HF were calculated using Poisson regression models. Among 4.9 million individuals included, 40 485 developed SA during the study period (median age: 53.4 years, 78.5% men) of whom 45.2% received CPAP therapy. Crude rates of HF were increased in all patients with SA relative to the background population. In the adjusted model, the incidence rate ratios of HF were increased in the untreated SA patients of all ages, compared with the background population. Comparing the CPAP‐treated patients with SA with the untreated patients with SA showed significantly lower incidence rate ratios of HF among older patients. Conclusions In this nationwide cohort study, SA not treated with CPAP was associated with an increased risk of HF in patients of all ages. Use of CPAP therapy was associated with a lower risk of incident HF in patients >60 years of age, suggesting a protective effect of CPAP therapy in the elderly.
Anders Holt; Jenny Bjerre; Bochra Zareini; Henning Koch; Philip Tønnesen; Gunnar H. Gislason; Olav W. Nielsen; Morten Schou; Morten Lamberts. Sleep Apnea, the Risk of Developing Heart Failure, and Potential Benefits of Continuous Positive Airway Pressure (CPAP) Therapy. Journal of the American Heart Association 2018, 7, e008684 .
AMA StyleAnders Holt, Jenny Bjerre, Bochra Zareini, Henning Koch, Philip Tønnesen, Gunnar H. Gislason, Olav W. Nielsen, Morten Schou, Morten Lamberts. Sleep Apnea, the Risk of Developing Heart Failure, and Potential Benefits of Continuous Positive Airway Pressure (CPAP) Therapy. Journal of the American Heart Association. 2018; 7 (13):e008684.
Chicago/Turabian StyleAnders Holt; Jenny Bjerre; Bochra Zareini; Henning Koch; Philip Tønnesen; Gunnar H. Gislason; Olav W. Nielsen; Morten Schou; Morten Lamberts. 2018. "Sleep Apnea, the Risk of Developing Heart Failure, and Potential Benefits of Continuous Positive Airway Pressure (CPAP) Therapy." Journal of the American Heart Association 7, no. 13: e008684.
Nick Mattsson; Olav Wendelboe Nielsen; Linda Johnson; Eva Prescott; Peter Schnohr; Gorm Boje Jensen; Lars Køber; Ahmad Sajadieh. The Reply. The American Journal of Medicine 2018, 131, e169 .
AMA StyleNick Mattsson, Olav Wendelboe Nielsen, Linda Johnson, Eva Prescott, Peter Schnohr, Gorm Boje Jensen, Lars Køber, Ahmad Sajadieh. The Reply. The American Journal of Medicine. 2018; 131 (4):e169.
Chicago/Turabian StyleNick Mattsson; Olav Wendelboe Nielsen; Linda Johnson; Eva Prescott; Peter Schnohr; Gorm Boje Jensen; Lars Køber; Ahmad Sajadieh. 2018. "The Reply." The American Journal of Medicine 131, no. 4: e169.
Potassium supplementation reduces the risk of cardiovascular mortality and stroke in population studies; however, the prognostic impact of mild hypokalemia in the general population has not been thoroughly investigated. We aimed to investigate associations between mild hypokalemia and endpoints in the general population. Participants (aged 48-76 years) from the general population study “Copenhagen City Heart Study” (n = 5916) were studied. Participants were divided into groups according to baseline values of plasma potassium (potassium): hypokalemia (4.5 mmol/L, n = 185). Hypokalemia was further divided as potassium <3.4 mmol/L and 3.4-3.6 mmol/L. The primary endpoints were all-cause mortality and nonfatal validated ischemic stroke. The secondary endpoint was acute myocardial infarction (AMI). We adjusted for conventional risk factors, diuretics, and atrial fibrillation at baseline. Mean potassium in the hypokalemic group was 3.5 mmol/L (range, 2.6-3.6 mmol/L) and was associated (P < 0.05) with increased systolic blood pressure, higher CHA2DS2-VASc score, and increased use of diuretics as compared with normokalemia. Baseline atrial fibrillation was equally frequent across groups. Median follow-up-time was 11.9 years (Q1-Q3: 11.4-12.5 years). Hypokalemia was borderline associated with increased stroke risk in a multivariable Cox model (including adjustment for competing risk) as compared with normokalemia (hazard ratio [HR] 1.40; 95% confidence interval [CI], 1.00-1.98). The subgroup with potassium <3.4 mmol/L had higher stroke risk (HR 2.10; 95% CI, 1.19-3.73) and mortality risk (HR 1.32; 95% CI, 1.01-1.74) as compared with normokalemia. Hypokalemia was not associated with AMI, and no increased risk of mortality was seen with concomitant AMI and hypokalemia. No associations were seen with high potassium. In a general population mild hypokalemia is associated with increased stroke risk and, to a lesser degree, increased mortality risk.
Nick Mattsson; Olav Wendelboe Nielsen; Linda Johnson; Eva Prescott; Peter Schnohr; Gorm Boje Jensen; Lars Køber; Ahmad Sajadieh. Prognostic Impact of Mild Hypokalemia in Terms of Death and Stroke in the General Population—A Prospective Population Study. The American Journal of Medicine 2017, 131, 318.e9 -318.e19.
AMA StyleNick Mattsson, Olav Wendelboe Nielsen, Linda Johnson, Eva Prescott, Peter Schnohr, Gorm Boje Jensen, Lars Køber, Ahmad Sajadieh. Prognostic Impact of Mild Hypokalemia in Terms of Death and Stroke in the General Population—A Prospective Population Study. The American Journal of Medicine. 2017; 131 (3):318.e9-318.e19.
Chicago/Turabian StyleNick Mattsson; Olav Wendelboe Nielsen; Linda Johnson; Eva Prescott; Peter Schnohr; Gorm Boje Jensen; Lars Køber; Ahmad Sajadieh. 2017. "Prognostic Impact of Mild Hypokalemia in Terms of Death and Stroke in the General Population—A Prospective Population Study." The American Journal of Medicine 131, no. 3: 318.e9-318.e19.
Background:Although air pollution and road traffic noise have been associated with higher risk of cardiovascular diseases, associations with heart failure have received only little attention.Objectives:We aimed to investigate whether long-term exposure to road traffic noise and nitrogen dioxide (NO2) were associated with incident heart failure.Methods:In a cohort of 57,053 people 50–64 y of age at enrollment in the period 1993–1997, we identified 2,550 cases of first-ever hospital admission for heart failure during a mean follow-up time of 13.4 y. Present and historical residential addresses from 1987 to 2011 were found in national registers, and road traffic noise (Lden) and NO2 were modeled for all addresses. Analyses were done using Cox proportional hazard model.Results:An interquartile range higher 10-y time-weighted mean exposure for Lden and NO2 was associated with incidence rate ratios (IRR) for heart failure of 1.14 (1.08–1.21) and 1.11 (1.07–1.16), respectively, in models adjusted for gender, lifestyle, and socioeconomic status. In models with mutual exposure adjustment, IRRs were 1.08 (1.00–1.16) for Lden and 1.07 (1.01–1.14) for NO2. We found statistically significant modification of the NO2–heart failure association by gender (strongest association among men), baseline hypertension (strongest association among hypertensive), and diabetes (strongest association among diabetics). The same tendencies were seen for noise, but interactions were not statistically significant.Conclusions:Long-term exposure to NO2 and road traffic noise was associated with higher risk of heart failure, mainly among men, in both single- and two-pollutant models. High exposure to both pollutants was associated with highest risk. https://doi.org/10.1289/EHP1272
Mette Sørensen; Olav Wendelboe Nielsen; Ahmad Sajadieh; Matthias Ketzel; Anne Tjonneland; Kim Overvad; Ole Raaschou-Nielsen. Long-Term Exposure to Road Traffic Noise and Nitrogen Dioxide and Risk of Heart Failure: A Cohort Study. Environmental Health Perspectives 2017, 125, 097021 .
AMA StyleMette Sørensen, Olav Wendelboe Nielsen, Ahmad Sajadieh, Matthias Ketzel, Anne Tjonneland, Kim Overvad, Ole Raaschou-Nielsen. Long-Term Exposure to Road Traffic Noise and Nitrogen Dioxide and Risk of Heart Failure: A Cohort Study. Environmental Health Perspectives. 2017; 125 (9):097021.
Chicago/Turabian StyleMette Sørensen; Olav Wendelboe Nielsen; Ahmad Sajadieh; Matthias Ketzel; Anne Tjonneland; Kim Overvad; Ole Raaschou-Nielsen. 2017. "Long-Term Exposure to Road Traffic Noise and Nitrogen Dioxide and Risk of Heart Failure: A Cohort Study." Environmental Health Perspectives 125, no. 9: 097021.
Background. Ischemic heart failure (IHF) has a poor prognosis in spite of optimal therapy. We have established a new allogeneic Cardiology Stem Cell Centre adipose-derived stromal cell (CSCC_ASC) product from healthy donors. It is produced without animal products, in closed bioreactor systems and cryopreserved as an off-the-shelf product ready to use. Study Design. A multicentre, double-blind, placebo-controlled phase II study with direct intramyocardial injections of allogeneic CSCC_ASC in patients with chronic IHF. A total of 81 patients will be randomised at 2 : 1 to CSCC_ASC or placebo. There is no HLA tissue type matching needed between the patients and the donors. Methods. The treatment will be delivered by direct injections into the myocardium. The primary endpoint is change in the left ventricle endsystolic volume at 6-month follow-up. Secondary endpoints are safety and changes in left ventricle ejection fraction, myocardial mass, stroke volume, and cardiac output. Other secondary endpoints are change in clinical symptoms, 6-minute walking test, and the quality of life after 6 and 12 months. Conclusion. The aim of the present study is to demonstrate safety and the regenerative efficacy of the allogeneic CSCC_ASC product from healthy donors in a double-blind, placebo-controlled, multicentre study in patients with IHF.
Jens Kastrup; Morten Schou; Ida Gustafsson; Olav Wendelboe Nielsen; Rasmus Møgelvang; Klaus Kofoed; Charlotte Kragelund; Jens Hove; Andreas Fabricius-Bjerre; Merete Heitman; Mandana Haack-Sørensen; Lisbeth Drozd Lund; Ellen Mønsted Johansen; Abbas Ali Qayyum; Anders Bruun Mathiasen; Annette Ekblond. Rationale and Design of the First Double-Blind, Placebo-Controlled Trial with Allogeneic Adipose Tissue-Derived Stromal Cell Therapy in Patients with Ischemic Heart Failure: A Phase II Danish Multicentre Study. Stem Cells International 2017, 2017, 1 -8.
AMA StyleJens Kastrup, Morten Schou, Ida Gustafsson, Olav Wendelboe Nielsen, Rasmus Møgelvang, Klaus Kofoed, Charlotte Kragelund, Jens Hove, Andreas Fabricius-Bjerre, Merete Heitman, Mandana Haack-Sørensen, Lisbeth Drozd Lund, Ellen Mønsted Johansen, Abbas Ali Qayyum, Anders Bruun Mathiasen, Annette Ekblond. Rationale and Design of the First Double-Blind, Placebo-Controlled Trial with Allogeneic Adipose Tissue-Derived Stromal Cell Therapy in Patients with Ischemic Heart Failure: A Phase II Danish Multicentre Study. Stem Cells International. 2017; 2017 ():1-8.
Chicago/Turabian StyleJens Kastrup; Morten Schou; Ida Gustafsson; Olav Wendelboe Nielsen; Rasmus Møgelvang; Klaus Kofoed; Charlotte Kragelund; Jens Hove; Andreas Fabricius-Bjerre; Merete Heitman; Mandana Haack-Sørensen; Lisbeth Drozd Lund; Ellen Mønsted Johansen; Abbas Ali Qayyum; Anders Bruun Mathiasen; Annette Ekblond. 2017. "Rationale and Design of the First Double-Blind, Placebo-Controlled Trial with Allogeneic Adipose Tissue-Derived Stromal Cell Therapy in Patients with Ischemic Heart Failure: A Phase II Danish Multicentre Study." Stem Cells International 2017, no. : 1-8.
The efficacy of closure of a patent foramen ovale (PFO) in the prevention of recurrent stroke after cryptogenic stroke is uncertain. We investigated the effect of PFO closure combined with antiplatelet therapy versus antiplatelet therapy alone on the risks of recurrent stroke and new brain infarctions. In this multinational trial involving patients with a PFO who had had a cryptogenic stroke, we randomly assigned patients, in a 2:1 ratio, to undergo PFO closure plus antiplatelet therapy (PFO closure group) or to receive antiplatelet therapy alone (antiplatelet-only group). Imaging of the brain was performed at the baseline screening and at 24 months. The coprimary end points were freedom from clinical evidence of ischemic stroke (reported here as the percentage of patients who had a recurrence of stroke) through at least 24 months after randomization and the 24-month incidence of new brain infarction, which was a composite of clinical ischemic stroke or silent brain infarction detected on imaging. We enrolled 664 patients (mean age, 45.2 years), of whom 81% had moderate or large interatrial shunts. During a median follow-up of 3.2 years, clinical ischemic stroke occurred in 6 of 441 patients (1.4%) in the PFO closure group and in 12 of 223 patients (5.4%) in the antiplatelet-only group (hazard ratio, 0.23; 95% confidence interval [CI], 0.09 to 0.62; P=0.002). The incidence of new brain infarctions was significantly lower in the PFO closure group than in the antiplatelet-only group (22 patients [5.7%] vs. 20 patients [11.3%]; relative risk, 0.51; 95% CI, 0.29 to 0.91; P=0.04), but the incidence of silent brain infarction did not differ significantly between the study groups (P=0.97). Serious adverse events occurred in 23.1% of the patients in the PFO closure group and in 27.8% of the patients in the antiplatelet-only group (P=0.22). Serious device-related adverse events occurred in 6 patients (1.4%) in the PFO closure group, and atrial fibrillation occurred in 29 patients (6.6%) after PFO closure. Among patients with a PFO who had had a cryptogenic stroke, the risk of subsequent ischemic stroke was lower among those assigned to PFO closure combined with antiplatelet therapy than among those assigned to antiplatelet therapy alone; however, PFO closure was associated with higher rates of device complications and atrial fibrillation. (Funded by W.L. Gore and Associates; Gore REDUCE ClinicalTrials.gov number, NCT00738894.)
Lars Søndergaard; Scott E. Kasner; John F. Rhodes; Grethe Andersen; Helle Klingenberg Iversen; Olav Wendelboe Nielsen; Magnus Settergren; Christina Sjöstrand; Risto O. Roine; David Hildick-Smith; J. David Spence; Lars Thomassen. Patent Foramen Ovale Closure or Antiplatelet Therapy for Cryptogenic Stroke. New England Journal of Medicine 2017, 377, 1033 -1042.
AMA StyleLars Søndergaard, Scott E. Kasner, John F. Rhodes, Grethe Andersen, Helle Klingenberg Iversen, Olav Wendelboe Nielsen, Magnus Settergren, Christina Sjöstrand, Risto O. Roine, David Hildick-Smith, J. David Spence, Lars Thomassen. Patent Foramen Ovale Closure or Antiplatelet Therapy for Cryptogenic Stroke. New England Journal of Medicine. 2017; 377 (11):1033-1042.
Chicago/Turabian StyleLars Søndergaard; Scott E. Kasner; John F. Rhodes; Grethe Andersen; Helle Klingenberg Iversen; Olav Wendelboe Nielsen; Magnus Settergren; Christina Sjöstrand; Risto O. Roine; David Hildick-Smith; J. David Spence; Lars Thomassen. 2017. "Patent Foramen Ovale Closure or Antiplatelet Therapy for Cryptogenic Stroke." New England Journal of Medicine 377, no. 11: 1033-1042.
The glucagon-like peptide-1 receptor agonist liraglutide has been shown to reduce blood pressure (BP) in clinical trials using office BP measurements. However, the effects of liraglutide on 24-h BP and on the diurnal variation in BP have not been explored sufficiently. Forty-one patients with type 2 diabetes and stable coronary artery disease were randomized to receive liraglutide or placebo to a backbone therapy of metformin in this double-blind, placebo-controlled 12 along with 12 weeks crossover study. Ambulatory blood pressure monitoring (ABPM) was performed at the start and end of each intervention. Twenty-four individuals completed all 24-h BP measurements. Liraglutide, when compared with placebo, did not induce any significant changes in mean 24-h SBP [difference +1.8 mmHg (95% confidence interval, 95% CI: −4.33 to 7.93)] or DBP [+4.2 mmHg (−0.74 to 9.17)]. Twenty-four-hour BP profiles revealed a trend for increase in evening SBP and DBP [+9.2 mmHg (95% CI: 1.1–17.2) and +9.7 mmHg (95% CI: 3.9–15.5), respectively]. Mean heart rate significantly increased after liraglutide [+7.6 bpm (95% CI: 2.56–12.62)]. Liraglutide did not affect the BP variability or the nocturnal BP dipping. We could not demonstrate any BP-lowering effect of liraglutide when using 24-h ABPM. Liraglutide exhibited diurnal variation in the effect on BP without affecting the BP variability or nocturnal BP dipping.
Preman Kumarathurai; Christian Anholm; Andreas Fabricius-Bjerre; Olav Wendelboe Nielsen; Ole Kristiansen; Sten Madsbad; Steen Bendix Haugaard; Ahmad Sajadieh. Effects of the glucagon-like peptide-1 receptor agonist liraglutide on 24-h ambulatory blood pressure in patients with type 2 diabetes and stable coronary artery disease. Journal of Hypertension 2017, 35, 1070 -1078.
AMA StylePreman Kumarathurai, Christian Anholm, Andreas Fabricius-Bjerre, Olav Wendelboe Nielsen, Ole Kristiansen, Sten Madsbad, Steen Bendix Haugaard, Ahmad Sajadieh. Effects of the glucagon-like peptide-1 receptor agonist liraglutide on 24-h ambulatory blood pressure in patients with type 2 diabetes and stable coronary artery disease. Journal of Hypertension. 2017; 35 (5):1070-1078.
Chicago/Turabian StylePreman Kumarathurai; Christian Anholm; Andreas Fabricius-Bjerre; Olav Wendelboe Nielsen; Ole Kristiansen; Sten Madsbad; Steen Bendix Haugaard; Ahmad Sajadieh. 2017. "Effects of the glucagon-like peptide-1 receptor agonist liraglutide on 24-h ambulatory blood pressure in patients with type 2 diabetes and stable coronary artery disease." Journal of Hypertension 35, no. 5: 1070-1078.
Background and Purpose— Stroke is independently associated with the common conditions of hypokalemia and supraventricular ectopy, and we hypothesize that the combination of excessive supraventricular ectopic activity and hypokalemia has a synergistic impact on the prognosis in terms of stroke in the general population. Methods— Subjects (55–75 years old) from the Copenhagen Holter Study cohort (N=671) with no history of atrial fibrillation or stroke were studied—including baseline values of potassium and ambulatory 48-hour Holter monitoring. Excessive supraventricular ectopic activity is defined as ≥30 premature atrial complexes per hour or any episodes of runs of ≥20. Hypokalemia was defined as plasma-potassium ≤3.6 mmol/L. The primary end point was ischemic stroke. Cox models were used. Results— Hypokalemia was mild (mean, 3.4 mmol/L; range, 2.7–3.6). Hypokalemic subjects were older (67.0±6.94 versus 64.0±6.66 years; P <0.0001) and more hypertensive (165.1±26.1 versus 154.6±23.5 mm Hg; P <0.0001). Median follow-up time was 14.4 years (Q1–Q3, 9.4–14.7 years). The incidence of stroke was significantly higher in the hypokalemic group (hazard ratio, 1.84; 95% confidence interval, 1.04–3.28) after covariate adjustments, as well as in a competing risk analysis with death (hazard ratio, 1.51; 95% confidence interval, 1.12–2.04). Excessive supraventricular ectopic activity was also associated with stroke (hazard ratio, 2.23; 95% confidence interval, 1.33–3.76). The combination of hypokalemia and excessive supraventricular ectopic activity increased the risk of events synergistically. Stroke rate was 93 per 1000 patient-year ( P <0.0001) in this group (n=17) compared with 6.9 (n=480); 11 (n=81), and 13 (n=93) per 1000 patient-year in the groups without the combination. Conclusions— The combination of hypokalemia and excessive supraventricular ectopy carries a poor prognosis in terms of stroke.
Nick Mattsson; Preman Kumarathurai; Bjørn Strøier Larsen; Olav Wendelboe Nielsen; Ahmad Sajadieh. Mild Hypokalemia and Supraventricular Ectopy Increases the Risk of Stroke in Community-Dwelling Subjects. Stroke 2017, 48, 537 -543.
AMA StyleNick Mattsson, Preman Kumarathurai, Bjørn Strøier Larsen, Olav Wendelboe Nielsen, Ahmad Sajadieh. Mild Hypokalemia and Supraventricular Ectopy Increases the Risk of Stroke in Community-Dwelling Subjects. Stroke. 2017; 48 (3):537-543.
Chicago/Turabian StyleNick Mattsson; Preman Kumarathurai; Bjørn Strøier Larsen; Olav Wendelboe Nielsen; Ahmad Sajadieh. 2017. "Mild Hypokalemia and Supraventricular Ectopy Increases the Risk of Stroke in Community-Dwelling Subjects." Stroke 48, no. 3: 537-543.
Aims The aims of the study were to investigate the effects of the GLP‐1 receptor agonist liraglutide as add‐on to metformin on insulin sensitivity (Si) and glucose effectiveness (Sg) in addition to its positive effects on beta‐cell function in overweight/obese patients with coronary artery disease (CAD) and type 2 diabetes mellitus (T2DM). Methods The design of the study was a randomized, double‐blind, placebo‐controlled, cross‐over trial in patients with stable CAD and newly diagnosed well‐controlled T2DM. Patients were treated with liraglutide/metformin vs placebo/metformin for a 12 + 12‐week period with ≥2‐week wash‐out. First phase insulin secretion (AIRg), Si and Sg were estimated by the Bergman Minimal Model, enabling calculation of beta‐cell function; Disposition Index (DI) = AIRg × Si. A total of 30 patients from among 41 randomized were available for paired analysis. Results Baseline characteristics were: HbA1c 47 mmol/mol (SD 6), BMI 31.6 kg/m2 (SD 4.8), fasting plasma‐glucose 6.9 mmol/L (IQR 6.1; 7.4) and HOMA‐IR 4.9 (IQR 3.0; 7.5). Liraglutide treatment improved AIRg by 3‐fold, 497 mU × L−1 × min (IQR 342; 626, P < .0001) and DI by 1‐fold, 766 (SD 824, P < .0001). Despite a significant weight loss of −2.7 kg (−6.7; −0.6) during liraglutide treatment, we found no improvement in HOMA‐IR, Si or Sg. Weight loss during liraglutide therapy did not result in a carry‐over effect. Conclusion Liraglutide as add‐on to metformin induces a clinically significant improvement in beta‐cell function in overweight/obese, high cardiovascular risk patients with newly diagnosed well‐controlled T2DM and CAD. The effect of liraglutide on DI is mediated entirely by improved AIRg whereas the effects on Si and Sg are neutral.
Christian Anholm; Preman Kumarathurai; Lene R. Pedersen; Olav W. Nielsen; Ole P. Kristiansen; Mogens Fenger; Sten Madsbad; Ahmad Sajadieh; Steen Bendix Haugaard. Liraglutide effects on beta-cell, insulin sensitivity and glucose effectiveness in patients with stable coronary artery disease and newly diagnosed type 2 diabetes. Diabetes, Obesity and Metabolism 2017, 19, 850 -857.
AMA StyleChristian Anholm, Preman Kumarathurai, Lene R. Pedersen, Olav W. Nielsen, Ole P. Kristiansen, Mogens Fenger, Sten Madsbad, Ahmad Sajadieh, Steen Bendix Haugaard. Liraglutide effects on beta-cell, insulin sensitivity and glucose effectiveness in patients with stable coronary artery disease and newly diagnosed type 2 diabetes. Diabetes, Obesity and Metabolism. 2017; 19 (6):850-857.
Chicago/Turabian StyleChristian Anholm; Preman Kumarathurai; Lene R. Pedersen; Olav W. Nielsen; Ole P. Kristiansen; Mogens Fenger; Sten Madsbad; Ahmad Sajadieh; Steen Bendix Haugaard. 2017. "Liraglutide effects on beta-cell, insulin sensitivity and glucose effectiveness in patients with stable coronary artery disease and newly diagnosed type 2 diabetes." Diabetes, Obesity and Metabolism 19, no. 6: 850-857.
Commercial self-monitoring devices are becoming increasingly popular, and over the last decade, the use of self-monitoring technology has spread widely in both consumer and medical markets. The purpose of this study was to evaluate five commercially available self-monitoring devices for further testing in clinical applications. Four activity trackers and one sleep tracker were evaluated based on step count validity and heart rate validity. Methods: The study enrolled 22 healthy volunteers in a walking test. Volunteers walked a 100 m track at 2 km/h and 3.5 km/h. Steps were measured by four activity trackers and compared to gyroscope readings. Two trackers were also tested on nine subjects by comparing pulse readings to Holter monitoring. Results: The lowest average systematic error in the walking tests was −0.2%, recorded on the Garmin Vivofit 2 at 3.5 km/h; the highest error was the Fitbit Charge HR at 2 km/h with an error margin of 26.8%. Comparisons of pulse measurements from the Fitbit Charge HR revealed a margin error of −3.42% ± 7.99% compared to the electrocardiogram. The Beddit sleep tracker measured a systematic error of −3.27% ± 4.60%. Conclusion: The measured results revealed the current functionality and limitations of the five self-tracking devices, and point towards a need for future research in this area.
Soren Leth; John Hansen; Olav W. Nielsen; Birthe Dinesen. Evaluation of Commercial Self-Monitoring Devices for Clinical Purposes: Results from the Future Patient Trial, Phase I. Sensors 2017, 17, 211 .
AMA StyleSoren Leth, John Hansen, Olav W. Nielsen, Birthe Dinesen. Evaluation of Commercial Self-Monitoring Devices for Clinical Purposes: Results from the Future Patient Trial, Phase I. Sensors. 2017; 17 (12):211.
Chicago/Turabian StyleSoren Leth; John Hansen; Olav W. Nielsen; Birthe Dinesen. 2017. "Evaluation of Commercial Self-Monitoring Devices for Clinical Purposes: Results from the Future Patient Trial, Phase I." Sensors 17, no. 12: 211.
We assessed the CT attenuation density of the pulmonary tissue adjacent to the heart in patients with acute non-ST segment elevation myocardial infarction (J.T. Kuhl, T.S. Kristensen, A.F. Thomsen et al., 2016) [1]. This data was related to the level of ground-glass opacification evaluated by a radiologist, and data on the interobserver variability of semi-automated assessment of pulmonary attenuation density was provided.
J. Tobias Kühl; Thomas S. Kristensen; Anna F. Thomsen; Louise Hindsø; Kristoffer L. Hansen; Olav W. Nielsen; Henning Kelbæk; Klaus F. Kofoed. Data on the quantitative assessment pulmonary ground-glass opacification from coronary computed tomography angiography datasets. Data in Brief 2016, 10, 6 -10.
AMA StyleJ. Tobias Kühl, Thomas S. Kristensen, Anna F. Thomsen, Louise Hindsø, Kristoffer L. Hansen, Olav W. Nielsen, Henning Kelbæk, Klaus F. Kofoed. Data on the quantitative assessment pulmonary ground-glass opacification from coronary computed tomography angiography datasets. Data in Brief. 2016; 10 ():6-10.
Chicago/Turabian StyleJ. Tobias Kühl; Thomas S. Kristensen; Anna F. Thomsen; Louise Hindsø; Kristoffer L. Hansen; Olav W. Nielsen; Henning Kelbæk; Klaus F. Kofoed. 2016. "Data on the quantitative assessment pulmonary ground-glass opacification from coronary computed tomography angiography datasets." Data in Brief 10, no. : 6-10.
J. Tobias Kühl; Thomas S. Kristensen; Anna F. Thomsen; Louise Hindsø; Kristoffer L. Hansen; Olav W. Nielsen; Henning Kelbæk; Klaus F. Kofoed. Clinical and prognostic correlates of pulmonary congestion in coronary computed tomography angiography data sets. Journal of Cardiovascular Computed Tomography 2016, 10, 466 -472.
AMA StyleJ. Tobias Kühl, Thomas S. Kristensen, Anna F. Thomsen, Louise Hindsø, Kristoffer L. Hansen, Olav W. Nielsen, Henning Kelbæk, Klaus F. Kofoed. Clinical and prognostic correlates of pulmonary congestion in coronary computed tomography angiography data sets. Journal of Cardiovascular Computed Tomography. 2016; 10 (6):466-472.
Chicago/Turabian StyleJ. Tobias Kühl; Thomas S. Kristensen; Anna F. Thomsen; Louise Hindsø; Kristoffer L. Hansen; Olav W. Nielsen; Henning Kelbæk; Klaus F. Kofoed. 2016. "Clinical and prognostic correlates of pulmonary congestion in coronary computed tomography angiography data sets." Journal of Cardiovascular Computed Tomography 10, no. 6: 466-472.
OBJECTIVE Reduced heart rate variability (HRV) and increased heart rate (HR) have been associated with cardiovascular mortality. Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) increase HR, and studies have suggested that they may reduce HRV. We examined the effect of the GLP-1 RA liraglutide on HRV and diurnal variation of HR in overweight patients with newly diagnosed type 2 diabetes (T2D) and stable coronary artery disease (CAD). RESEARCH DESIGN AND METHODS Liraglutide or placebo was administrated to a backbone therapy of metformin in this double-blind, placebo-controlled 12 + 12–week crossover study. SD of beat-to-beat (NN) intervals (SDNN) was assessed by 24-h Holter monitoring as a measure of HRV. Diurnal HR variation and sympathovagal balance analyzed by root mean square of successive differences (RMSSD) in NN intervals and high-frequency (HF) and low-frequency (LF) power were assessed. RESULTS Compared with placebo, liraglutide decreased SDNN in 27 subjects (−33.9 ms; P < 0.001, paired analysis); decreased RMSSD (−0.3 log-ms; P = 0.025); and increased the mean HR (8.1 beats/min; P = 0.003), daytime HR (5.7; P = 0.083), and nighttime HR (6.3; P = 0.026). In a multivariable regression analysis, the decrease in SDNN remained significant after adjustment for metabolic and HR changes. Liraglutide reduced HF power (−0.7 log-ms2; P = 0.026) without any change in LF/HF ratio. CONCLUSIONS In overweight patients with CAD and newly diagnosed T2D, liraglutide increased HR and reduced HRV despite significant weight loss and improvement in metabolic parameters. The increase in nightly HR in conjunction with a decrease in parameters of parasympathetic activity suggests that liraglutide may affect sympathovagal balance.
Preman Kumarathurai; Christian Anholm; Bjørn S. Larsen; Rasmus Huan Olsen; Sten Madsbad; Ole Kristiansen; Olav W. Nielsen; Steen Bendix Haugaard; Ahmad Sajadieh. Effects of Liraglutide on Heart Rate and Heart Rate Variability: A Randomized, Double-Blind, Placebo-Controlled Crossover Study. Diabetes Care 2016, 40, 117 -124.
AMA StylePreman Kumarathurai, Christian Anholm, Bjørn S. Larsen, Rasmus Huan Olsen, Sten Madsbad, Ole Kristiansen, Olav W. Nielsen, Steen Bendix Haugaard, Ahmad Sajadieh. Effects of Liraglutide on Heart Rate and Heart Rate Variability: A Randomized, Double-Blind, Placebo-Controlled Crossover Study. Diabetes Care. 2016; 40 (1):117-124.
Chicago/Turabian StylePreman Kumarathurai; Christian Anholm; Bjørn S. Larsen; Rasmus Huan Olsen; Sten Madsbad; Ole Kristiansen; Olav W. Nielsen; Steen Bendix Haugaard; Ahmad Sajadieh. 2016. "Effects of Liraglutide on Heart Rate and Heart Rate Variability: A Randomized, Double-Blind, Placebo-Controlled Crossover Study." Diabetes Care 40, no. 1: 117-124.
The benefit of an implantable cardioverter-defibrillator (ICD) in patients with symptomatic systolic heart failure caused by coronary artery disease has been well documented. However, the evidence for a benefit of prophylactic ICDs in patients with systolic heart failure that is not due to coronary artery disease has been based primarily on subgroup analyses. The management of heart failure has improved since the landmark ICD trials, and many patients now receive cardiac resynchronization therapy (CRT). In a randomized, controlled trial, 556 patients with symptomatic systolic heart failure (left ventricular ejection fraction, ≤35%) not caused by coronary artery disease were assigned to receive an ICD, and 560 patients were assigned to receive usual clinical care (control group). In both groups, 58% of the patients received CRT. The primary outcome of the trial was death from any cause. The secondary outcomes were sudden cardiac death and cardiovascular death. After a median follow-up period of 67.6 months, the primary outcome had occurred in 120 patients (21.6%) in the ICD group and in 131 patients (23.4%) in the control group (hazard ratio, 0.87; 95% confidence interval [CI], 0.68 to 1.12; P=0.28). Sudden cardiac death occurred in 24 patients (4.3%) in the ICD group and in 46 patients (8.2%) in the control group (hazard ratio, 0.50; 95% CI, 0.31 to 0.82; P=0.005). Device infection occurred in 27 patients (4.9%) in the ICD group and in 20 patients (3.6%) in the control group (P=0.29). In this trial, prophylactic ICD implantation in patients with symptomatic systolic heart failure not caused by coronary artery disease was not associated with a significantly lower long-term rate of death from any cause than was usual clinical care. (Funded by Medtronic and others; DANISH ClinicalTrials.gov number, NCT00542945 .).
Lars Køber; Jens Jakob Thune; Olav Wendelboe Nielsen; Jens Haarbo; Lars Videbæk; Eva Korup; Gunnar Jensen; Per Hildebrandt; Flemming Hald Steffensen; Niels Eske Bruun; Hans Eiskjær; Axel Brandes; Anna M. Thøgersen; Finn Gustafsson; Kenneth Egstrup; Regitze Videbæk; Christian Hassager; Jesper Hastrup Svendsen; Dan E. Høfsten; Christian Torp-Pedersen; Steen Pehrson. Defibrillator Implantation in Patients with Nonischemic Systolic Heart Failure. New England Journal of Medicine 2016, 375, 1221 -1230.
AMA StyleLars Køber, Jens Jakob Thune, Olav Wendelboe Nielsen, Jens Haarbo, Lars Videbæk, Eva Korup, Gunnar Jensen, Per Hildebrandt, Flemming Hald Steffensen, Niels Eske Bruun, Hans Eiskjær, Axel Brandes, Anna M. Thøgersen, Finn Gustafsson, Kenneth Egstrup, Regitze Videbæk, Christian Hassager, Jesper Hastrup Svendsen, Dan E. Høfsten, Christian Torp-Pedersen, Steen Pehrson. Defibrillator Implantation in Patients with Nonischemic Systolic Heart Failure. New England Journal of Medicine. 2016; 375 (13):1221-1230.
Chicago/Turabian StyleLars Køber; Jens Jakob Thune; Olav Wendelboe Nielsen; Jens Haarbo; Lars Videbæk; Eva Korup; Gunnar Jensen; Per Hildebrandt; Flemming Hald Steffensen; Niels Eske Bruun; Hans Eiskjær; Axel Brandes; Anna M. Thøgersen; Finn Gustafsson; Kenneth Egstrup; Regitze Videbæk; Christian Hassager; Jesper Hastrup Svendsen; Dan E. Høfsten; Christian Torp-Pedersen; Steen Pehrson. 2016. "Defibrillator Implantation in Patients with Nonischemic Systolic Heart Failure." New England Journal of Medicine 375, no. 13: 1221-1230.